Compare
Gilead Sciences vs Ligand Pharmaceuticals (GILD vs LGND)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Gilead Sciences (GILD) returned +36.1% and Ligand Pharmaceuticals (LGND) +60.8%; so far this year the figures are +36.0% and +62.0%.
Gilead Sciences is the larger company by market value, about 33.8 times the size of Ligand Pharmaceuticals.
Revenue grew +6.5% at GILD and +1.0% at LGND over the last year.
GILD yields 1.95%. LGND pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| GILD | LGND | |
|---|---|---|
| Price | $166.89 | $306.20 |
| 1-day | -0.41% | +2.41% |
| YTD | +35.97% | +61.95% |
| 1 year | +36.15% | +60.84% |
| 3 years | +108.12% | +474.48% |
| Market cap | $207.0B | $6.1B |
| P/E | — | 133.1 |
| P/S | 6.68 | 24.13 |
| P/B | 15.87 | 6.37 |
| Revenue growth | +6.50% | +1.00% |
| EPS growth | -149.00% | +13.30% |
| Gross margin % | 79.9 | 96.6 |
| Net margin % | -12.5 | 20.3 |
| ROE % | -29.6 | 5.4 |
| Debt / equity | 2.01 | 1.17 |
| FCF yield % | 6.7 | 1.5 |
| Dividend yield % | 1.95 | — |
| Beta | 0.37 | 0.85 |
| RSI (14) | 60.2 | 50.1 |
| Technical rating |